These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1026 related articles for article (PubMed ID: 32846967)

  • 1. Perspectives on Triple-Negative Breast Cancer: Current Treatment Strategies, Unmet Needs, and Potential Targets for Future Therapies.
    Gupta GK; Collier AL; Lee D; Hoefer RA; Zheleva V; Siewertsz van Reesema LL; Tang-Tan AM; Guye ML; Chang DZ; Winston JS; Samli B; Jansen RJ; Petricoin EF; Goetz MP; Bear HD; Tang AH
    Cancers (Basel); 2020 Aug; 12(9):. PubMed ID: 32846967
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Persistent EGFR/K-RAS/SIAH pathway activation drives chemo-resistance and early tumor relapse in triple-negative breast cancer.
    Tang AH; Hoefer RA; Guye ML; Bear HD
    Cancer Drug Resist; 2022; 5(3):691-702. PubMed ID: 36176751
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Unmet Clinical Need: Developing Prognostic Biomarkers and Precision Medicine to Forecast Early Tumor Relapse, Detect Chemo-Resistance and Improve Overall Survival in High-Risk Breast Cancer.
    Gupta G; Lee CD; Guye ML; Van Sciver RE; Lee MP; Lafever AC; Pang A; Tang-Tan AM; Winston JS; Samli B; Jansen RJ; Hoefer RA; Tang AH
    Ann Breast Cancer Ther; 2020 May; 4(1):48-57. PubMed ID: 32542231
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SIAH and EGFR, Two RAS Pathway Biomarkers, are Highly Prognostic in Locally Advanced and Metastatic Breast Cancer.
    van Reesema LLS; Zheleva V; Winston JS; Jansen RJ; O'Connor CF; Isbell AJ; Bian M; Qin R; Bassett PT; Hinson VJ; Dorsch KA; Kirby BW; Van Sciver RE; Tang-Tan AM; Harden EA; Chang DZ; Allen CA; Perry RR; Hoefer RA; Tang AH
    EBioMedicine; 2016 Sep; 11():183-198. PubMed ID: 27569656
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recent Advances in Immunotherapy and Targeted Therapy of Triple Negative Breast Cancer.
    Shewale H; Kanugo A
    Curr Pharm Biotechnol; 2024 Jul; ():. PubMed ID: 39092645
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Triple negative breast cancer: approved treatment options and their mechanisms of action.
    Mandapati A; Lukong KE
    J Cancer Res Clin Oncol; 2023 Jul; 149(7):3701-3719. PubMed ID: 35976445
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Advancements in the Treatment of Triple-Negative Breast Cancer: A Narrative Review of the Literature.
    Landry I; Sumbly V; Vest M
    Cureus; 2022 Feb; 14(2):e21970. PubMed ID: 35282535
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A New Strategy to Control and Eradicate "Undruggable" Oncogenic K-RAS-Driven Pancreatic Cancer: Molecular Insights and Core Principles Learned from Developmental and Evolutionary Biology.
    Van Sciver RE; Lee MP; Lee CD; Lafever AC; Svyatova E; Kanda K; Colliver AL; Siewertsz van Reesema LL; Tang-Tan AM; Zheleva V; Bwayi MN; Bian M; Schmidt RL; Matrisian LM; Petersen GM; Tang AH
    Cancers (Basel); 2018 May; 10(5):. PubMed ID: 29757973
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeted Therapeutic Strategies for Triple-Negative Breast Cancer.
    Li Y; Zhan Z; Yin X; Fu S; Deng X
    Front Oncol; 2021; 11():731535. PubMed ID: 34778045
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The evolving management of metastatic triple negative breast cancer.
    Malhotra MK; Emens LA
    Semin Oncol; 2020 Aug; 47(4):229-237. PubMed ID: 32563561
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular Biology Mechanisms and Emerging Therapeutics of Triple-Negative Breast Cancer.
    Zhang Z; Zhang R; Li D
    Biologics; 2023; 17():113-128. PubMed ID: 37767463
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Progress and pitfalls in the use of immunotherapy for patients with triple negative breast cancer.
    Agostinetto E; Losurdo A; Nader-Marta G; Santoro A; Punie K; Barroso R; Popovic L; Solinas C; Kok M; de Azambuja E; Lambertini M
    Expert Opin Investig Drugs; 2022 Jun; 31(6):567-591. PubMed ID: 35240902
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Triple-negative breast cancer: advancements in characterization and treatment approach.
    Hurvitz S; Mead M
    Curr Opin Obstet Gynecol; 2016 Feb; 28(1):59-69. PubMed ID: 26694831
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Research Progress on Molecular Subtyping and Modern Treatment of Triple-Negative Breast Cancer.
    Tong L; Yu X; Wang S; Chen L; Wu Y
    Breast Cancer (Dove Med Press); 2023; 15():647-658. PubMed ID: 37644916
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular Mechanisms, Biomarkers and Emerging Therapies for Chemotherapy Resistant TNBC.
    Ferrari P; Scatena C; Ghilli M; Bargagna I; Lorenzini G; Nicolini A
    Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163586
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Is the Androgen Receptor a Viable Target in Triple Negative Breast Cancer in 5 Years?
    Sharifi MN; O'Regan RM; Wisinski KB
    Clin Breast Cancer; 2023 Dec; 23(8):813-824. PubMed ID: 37419745
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Kinase inhibitors for precision therapy of triple-negative breast cancer: Progress, challenges, and new perspectives on targeting this heterogeneous disease.
    Mehlich D; Marusiak AA
    Cancer Lett; 2022 Oct; 547():215775. PubMed ID: 35667515
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Triple negative breast cancer: looking for the missing link between biology and treatments.
    Palma G; Frasci G; Chirico A; Esposito E; Siani C; Saturnino C; Arra C; Ciliberto G; Giordano A; D'Aiuto M
    Oncotarget; 2015 Sep; 6(29):26560-74. PubMed ID: 26387133
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Potential therapeutic targets of triple-negative breast cancer based on its intrinsic subtype.
    Shao F; Sun H; Deng CX
    Oncotarget; 2017 Sep; 8(42):73329-73344. PubMed ID: 29069872
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Research advances and new challenges in overcoming triple-negative breast cancer.
    Zong Y; Pegram M
    Cancer Drug Resist; 2021; 4(3):517-542. PubMed ID: 34888495
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 52.